374 related articles for article (PubMed ID: 36010869)
1. Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.
Derouane F; van Marcke C; Berlière M; Gerday A; Fellah L; Leconte I; Van Bockstal MR; Galant C; Corbet C; Duhoux FP
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010869
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
4. Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation.
Pelizzari G; Gerratana L; Basile D; Fanotto V; Bartoletti M; Liguori A; Fontanella C; Spazzapan S; Puglisi F
Cancer Treat Rev; 2019 Jan; 72():7-14. PubMed ID: 30414986
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
6. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
Spring LM; Bar Y; Isakoff SJ
J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
[TBL] [Abstract][Full Text] [Related]
8. Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer.
Martínez-Sáez O; Waks AG
Curr Treat Options Oncol; 2023 May; 24(5):479-495. PubMed ID: 36995527
[TBL] [Abstract][Full Text] [Related]
9. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract][Full Text] [Related]
10. Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer.
Hayashi M; Yamamoto Y; Iwase H
Chin Clin Oncol; 2020 Jun; 9(3):31. PubMed ID: 32594748
[TBL] [Abstract][Full Text] [Related]
11. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
Kim R; Osaki A; Toge T
Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
Provenzano E
Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
[TBL] [Abstract][Full Text] [Related]
14. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
[No Abstract] [Full Text] [Related]
15. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.
Iwamoto T; Kajiwara Y; Zhu Y; Iha S
Chin Clin Oncol; 2020 Jun; 9(3):27. PubMed ID: 32192349
[TBL] [Abstract][Full Text] [Related]
16. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
18. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
[TBL] [Abstract][Full Text] [Related]
19. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS; Bieche I; Lehmann-Che J; Scott V; Bertheau P; Guinebretière JM; Matthieu MC; Sigal-Zafrani B; Tembo O; Marty M; Asselain B; Spyratos F; de Cremoux P
Breast Cancer Res Treat; 2016 Oct; 159(3):499-511. PubMed ID: 27592112
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]